FTC Affiliate Disclosure: This article may contain affiliate links. If you enroll through a link in this article, a commission may be earned at no additional cost to you. This does not influence editorial content.
On April 2, 2026, the New York Times published a profile of Matthew Gallagher and his telehealth startup MEDVi that went viral within hours — $401 million in first-year revenue, two employees, a $1.8 billion projection for 2026. The story framed MEDVi as proof that AI could enable a solo founder to build a billion-dollar company. What most of the celebration coverage left out: the FDA had already sent MEDVi a warning letter six weeks earlier, and the agency was in the middle of the most aggressive enforcement sweep the compounded GLP-1 market has ever seen.
On March 3, 2026, the FDA issued warning letters to more than 30 telehealth companies in a single action. FDA Commissioner Marty Makary called it a “new era.” The agency said it had sent thousands of warning letters over the preceding six months — more than the cumulative total of the prior decade. MEDVi received its letter in February, before the larger batch. But the enforcement wave is not about one company. It is about the entire structure of how compounded GLP-1 medications are marketed and sold to consumers through telehealth.
This article explains what is happening, why, and what it means for every patient currently enrolled in a compounded GLP-1 program.
What the FDA's Warning Letters Target
The enforcement actions center on two violations:
Claims implying sameness with FDA-approved products. Telehealth companies have marketed compounded semaglutide and tirzepatide using language suggesting equivalence to Wegovy, Ozempic, Mounjaro, and Zepbound. The FDA's position: compounded medications are not the same. They have not been reviewed for safety, effectiveness, or quality.
Obscuring product sourcing. Companies — including MEDVi per its February warning letter — branded compounded products under the telehealth company's name without making clear that a separate compounding pharmacy prepared the medication. The FDA considers this misbranding.
These violations go to informed consent. Patients have the right to know what they are taking, who made it, and whether the FDA has reviewed it. Marketing that obscures any of those facts undermines that right.
Why the Enforcement Is Accelerating Now
Three forces are converging:
Drug shortages are resolving. The legal basis for most compounded GLP-1 activity rests on the FDA's drug shortage list. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding when commercially available products are unavailable or in shortage. In February 2025, the FDA declared the semaglutide shortage resolved for certain formulations. As Novo Nordisk and Eli Lilly increase manufacturing capacity, more formulations are expected to come off the list. When that happens, the legal foundation for compounding those specific medications shifts significantly.
Branded manufacturers are fighting back. Novo Nordisk filed a patent infringement lawsuit against Hims & Hers in early 2026. Eli Lilly has signaled similar intent regarding tirzepatide. If brand-name manufacturers win, the legal precedent could restrict compounding across the entire market.
Advertising enforcement is intensifying. The FDA launched a crackdown on misleading DTC pharmaceutical advertising in September 2025. A bipartisan coalition of 35 state attorneys general wrote to Meta about AI-generated weight-loss ads in December 2025. MEDVi alone has more than 5,000 active ads on Meta's platform. The convergence of federal and state attention means companies relying on aggressive paid media face pressure from multiple directions.
How Interconnected the Market Really Is
A STAT News investigation in March 2026 revealed something most consumers do not realize: among more than 70 telehealth companies warned by the FDA, at least 30 percent shared clinical ties to just four medical groups — OpenLoop Health, Beluga Health, MD Integrations, and Telegra.
This means many consumer-facing brands that appear to be independent competitors actually share the same clinical infrastructure. When a patient switches from one provider to another, they may be changing the brand on the website while getting care from the same underlying network.
For patients, the implication is direct. If a clinical partner faces enforcement action, a data breach, or litigation, the effects ripple across every brand on that platform. OpenLoop Health — which provides clinical services for MEDVi and other brands — disclosed a January 2026 data breach affecting up to 1.6 million patients and faces class-action litigation over the efficacy of compounded oral tirzepatide. Switching telehealth brands does not necessarily insulate you from infrastructure-level problems if the new brand uses the same clinical partner.
What This Means for Current Compounded GLP-1 Patients
If you are enrolled in any compounded GLP-1 program — MEDVi, Hims, Ro, Henry Meds, or another provider — the regulatory changes may affect your treatment:
Your medication may become harder to get. As drugs come off the shortage list, compounding pharmacies may lose the legal basis to prepare them. This does not happen overnight, and legal challenges are likely. But the availability of compounded GLP-1 medications is not guaranteed to remain stable through 2026.
Your provider may change its offerings. Companies may need to add brand-name paths, adjust pricing, or restructure their models. MEDVi has already added brand-name Wegovy and Zepbound options alongside compounded products.
Pricing may go up. Compounded versions are cheaper because they skip FDA approval costs. If the compounded market contracts, the pricing advantage could narrow or disappear.
Your data may be at risk through partner systems. The OpenLoop breach demonstrates that patient risk in three-party telehealth extends beyond the consumer brand to the infrastructure layer.
Where MEDVi Fits in This Picture
MEDVi is neither the cause of the crackdown nor its primary target. It is one of dozens operating in a market that grew faster than regulators could keep pace. Its February 2026 warning letter addresses the same marketing violations flagged across 30-plus companies in March.
What makes MEDVi distinctive is the scale. NYT-verified $401 million in 2025 revenue. A $1.8 billion 2026 projection. More than 5,000 active ads on Meta. Two employees running the entire operation with AI tools. That profile — built through the NYT story going viral — may attract disproportionate regulatory attention compared to lower-profile competitors selling the same products through the same infrastructure.
MEDVi holds LegitScript certification. It has 11,400-plus Trustpilot reviews at 4.4 to 4.5 stars. Compounded semaglutide starts at $179 for the first month, $299 refills. Tirzepatide at $349. Many patients report positive outcomes. The company has added brand-name paths — which may position it better than competitors who have not if the compounded market contracts further.
Whether MEDVi can sustain its growth while the regulatory ground shifts is an open question. The same question applies to every company in this space.
What Patients Should Do Now
Know who provides your clinical care. Check your enrollment materials to identify the medical group behind your prescriptions. If it is OpenLoop Health, know about the breach and litigation.
Talk to your personal physician. If the regulatory situation changes — for example, your medication comes off the shortage list — your doctor can help you evaluate alternatives or transition your treatment.
Understand your billing terms. If your provider changes offerings or discontinues a product line, know your options. MEDVi requires 72-hour notice before billing date. Read the terms for whatever provider you use.
Stay informed. The FDA's drug shortage list is at accessdata.fda.gov. Warning letters are at fda.gov. Monitoring these gives you advance notice of changes that could affect your access.
Consider branded medication if you can afford it. FDA-approved Wegovy and Zepbound offer manufacturing consistency and regulatory stability that compounded products do not. If your insurance covers it or you can manage the cash price, branded medication is the more stable long-term option.
Frequently Asked Questions
Are compounded GLP-1 medications going away?
Not necessarily, but the market is contracting. As shortages resolve, the legal basis narrows. FDA enforcement is increasing. Patent litigation adds pressure. Some products may become unavailable in 2026. Have a backup plan.
Why is MEDVi in the news right now?
The NYT profiled MEDVi on April 2, 2026, reporting $401 million in 2025 revenue with two employees and a $1.8 billion 2026 projection. The company simultaneously faces an FDA warning letter, a clinical partner data breach, and pending litigation. Both the growth story and the regulatory questions are real.
How many companies received FDA warning letters?
More than 30 in March 2026 alone. Over the preceding six months, the FDA sent thousands of warning and cease-and-desist letters — more than the cumulative total of the prior decade.
Does MEDVi still sell compounded GLP-1s?
As of April 2026, yes. Semaglutide at $179 first month ($299 refills), tirzepatide at $349, oral tablets at $249. The company has also added brand-name Wegovy and Zepbound. Verify current availability on their website — offerings may change based on regulatory developments.
Should I switch from compounded to brand-name GLP-1?
If you have insurance that covers it or can manage the price, brand-name medication offers FDA review, manufacturing consistency, and regulatory stability. If not, compounded versions remain available through multiple providers as of April 2026 — but understand the regulatory risks. Discuss the decision with your doctor.
Is MEDVi's LegitScript certification still valid?
Yes, as of April 2026. Verify any provider's status at legitscript.com.
This article is for informational purposes only. GLP-1 medications require a prescription. Compounded medications are not FDA-approved finished products. The regulatory environment is changing rapidly. Consult licensed professionals for medical and legal guidance.
SigMedical.net Editorial Team | Published April 2026
Leave a Reply
You must be logged in to post a comment.